Secukinumab (AIN-457) for the treatment of Psoriasis

被引：10

作者：

Jaleel, Tarannum ^{[1
]}

Elmets, Craig ^{[1
]}

Weinkle, Allison ^{[3
]}

Kassira, Sama ^{[2
]}

Elewski, Boni ^{[1
]}

机构：

[1] Univ Alabama Birmingham, Dept Dermatol, EFH 414,1530 3rd Ave S, Birmingham, AL 35294 USA

[2] Univ Alabama Birmingham, Sch Med, Birmingham, AL 35294 USA

[3] Univ Calif San Diego, Sch Med, La Jolla, CA 92093 USA

来源：

EXPERT REVIEW OF CLINICAL PHARMACOLOGY | 2016年 / 9卷 / 02期

关键词：

pharmacology; IL-17; Th; 17; AIN-457; psoriasis; secukinumab; SEVERE PLAQUE PSORIASIS; RANDOMIZED CONTROLLED-TRIAL; ANTI-INTERLEUKIN-17A MONOCLONAL-ANTIBODY; TO-SEVERE PSORIASIS; DOUBLE-BLIND; PHASE-III; OPEN-LABEL; MULTIPLE-SCLEROSIS; TH17; CELLS; INFLIXIMAB INDUCTION;

D O I：

10.1586/17512433.2016.1129894

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Secukinumab (also known as AIN-457) is a human monoclonal antibody targeting IL-17A, which has been recently FDA-approved for the treatment of moderate to severe psoriasis and psoriatic arthritis with coexistent moderate to severe plaque psoriasis based on clinical trials demonstrating excellent efficacy. This review will address the rationale for targeting the IL-23/Th17/IL-17 axis, the role of IL-17 and Th17 cells in psoriasis and other chronic inflammatory diseases, and will examine pre-clinical studies, pharmacologic properties, clinical efficacy, and the safety profile of secukinumab.

引用

页码：187 / 202

页数：16

共 50 条

[1] Secukinumab (AIN457) for the treatment of psoriasis
Lopez-Ferrer, Anna
Vilarrasa, Eva
Puig, Lluis
EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2015, 11 (11) : 1177 - 1188
[2] Secukinumab (AIN457) in the treatment of ankylosing spondylitis
Braun, Juergen
Baraliakos, Xenofon
Kiltz, Uta
EXPERT OPINION ON BIOLOGICAL THERAPY, 2016, 16 (05) : 711 - 722
[3] A review of secukinumab in psoriasis treatment
Berg, Scott H.
Balogh, Esther A.
Ghamrawi, Rima, I
Feldman, Steven R.
IMMUNOTHERAPY, 2021, 13 (03) : 201 - 216
[4] Safety of secukinumab in the treatment of psoriasis
Blauvelt, Andrew
EXPERT OPINION ON DRUG SAFETY, 2016, 15 (10) : 1413 - 1420
[5] US real-world effectiveness of secukinumab for the treatment of psoriasis: 6-month analysis from the Corrona Psoriasis Registry
Strober, Bruce E.
Germino, Rebecca
Guana, Adriana
Greenberg, Jeffrey D.
Litman, Heather J.
Guo, Ning
Lebwohl, Mark
JOURNAL OF DERMATOLOGICAL TREATMENT, 2020, 31 (04) : 333 - 341
[6] Secukinumab in the treatment of psoriasis: an update
Reszke, Radomir
Szepietowski, Jacek C.
IMMUNOTHERAPY, 2017, 9 (03) : 229 - 238
[7] Secukinumab: a review of the anti-IL-17A biologic for the treatment of psoriasis
Frieder, Jillian
Kivelevitch, Dario
Menter, Alan
THERAPEUTIC ADVANCES IN CHRONIC DISEASE, 2018, 9 (01) : 5 - 21
[8] Scalp psoriasis: report of efficient treatment with secukinumab
Pistone, Giuseppe
Tilotta, Giovanna
Gurreri, Rosario
Curiale, Salvatrice
Bongiorno, Maria Rita
JOURNAL OF DERMATOLOGICAL TREATMENT, 2018, 29 : 14 - 16
[9] Secukinumab, ixekizumab, bimekizumab and brodalumab for the treatment of psoriasis and psoriatic arthritis
Simopoulou, Theodora
Tsiogkas, Sotirios G.
Zafiriou, Efterpi
Bogdanos, Dimitrios P.
DRUGS OF TODAY, 2023, 59 (03) : 135 - 167
[10] Secukinumab in the Treatment of Psoriasis: A Narrative Review on Early Treatment and Real-World Evidence
Malagoli, Piergiorgio
Dapavo, Paolo
Amerio, Paolo
Atzori, Laura
Balato, Anna
Bardazzi, Federico
Bianchi, Luca
Cattaneo, Angelo
Chiricozzi, Andrea
Congedo, Maurizio
Fargnoli, Maria Concetta
Giofre, Claudia
Gisondi, Paolo
Guarneri, Claudio
Lembo, Serena
Loconsole, Francesco
Mazzocchetti, Giampiero
Mercuri, Santo Raffaele
Morrone, Pietro
Offidani, Anna Maria
Palazzo, Giovanni
Parodi, Aurora
Pellacani, Giovanni
Piaserico, Stefano
Potenza, Concetta
Prignano, Francesca
Romanelli, Marco
Savoia, Paola
Stingeni, Luca
Travaglini, Massimo
Trovato, Emanuele
Venturini, Marina
Zichichi, Leonardo
Costanzo, Antonio
DERMATOLOGY AND THERAPY, 2024, 14 (10) : 2739 - 2757

← 1 2 3 4 5 →